Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Baxter

Jack Henry & Associates

Johnson & Johnson

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

It’s been 100 years since the United States and the world has encountered a pandemic like COVID-19.

5 Stocks to Buy Now for a W-Shaped Recovery With a Long Recession

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline

ACADIA Pharma

Biogen

Boyd Gaming

Hill-Rom Hlds

Royal Caribbean Cruises

Teladoc

Thor Industries

UnitedHealth Group

Ventas

Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.

10 Stocks to Buy for an Aging Population

BATON ROUGE, La., April  27, 2020  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and personal care, announced today that it has, through one of its wholly owned subsidiaries, signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice (“AseraCare Hospice”), a national hospice care provider with an executive office in Plano, Texas and administrative support center in Fort Smith, Arkansas. Founded in 1994, AseraCare Hospice cares for more than 2,100 patients daily and employs more than 1,200 hospice professionals in 44 locations across 14 states, generating approximately $117 million in annual revenues.

Amedisys Signs Definitive Agreement to Acquire AseraCare Hospice

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

Amazon

Chewy

DocuSign

Five9

Eli Lilly

Masimo

Moderna

Netflix

Walmart

The COVID-19 pandemic staggered economic activity and decreased consumer spending.

10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic

Atmos Energy

AeroVironment

Chemed

NextEra Energy

To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.

Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amedisys (AMED) Upgraded to Buy: Here's Why

Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amedisys (AMED) Hits 52-Week High, Can the Run Continue?

Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.

Amedisys Gains on Expanding Hospice Arm, Favorable Demography

In the latest trading session, Amedisys (AMED) closed at $168.20, marking a -0.87% move from the previous day.

Amedisys (AMED) Stock Moves -0.87%: What You Should Know

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

Why Is Amedisys (AMED) Down 16.2% Since Last Earnings Report?

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Amedisys (AMED)

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2019 Results - Earnings Call Transcript

A revenue miss and a narrow earnings beat weren't what investors hoped for in Q4.

Why Amedisys' Q4 Results Could Be a Speed Bump for the High-Flying Stock

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Amedisys (AMED) is Poised to Beat Earnings Estimates Again

Amedisys (AMED) closed the most recent trading day at $195.13, moving +1.28% from the previous trading session.

Amedisys (AMED) Outpaces Stock Market Gains: What You Should Know

Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice

Chevron

MDU Resources Group

Gibraltar Industries

With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.

Buy These 5 Low Leverage Stocks This Earnings Season

Brookfield Business Partners

Enphase Energy

Match Group

Pure Storage

Historically, during the Year of the Rat, the S&P 500's performance has been slightly better than the than the index's overall average of 11.4%.

Year of the Rat Spells Good Times for Wall Street: 5 Picks

Is  (AMED) Outperforming Other Medical Stocks This Year?

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

Chico's FAS

Ichor Hlds

MagnaChip Semiconductor

PBF Logistics

It seems that Wall Street bulls have no intention of taking a breather after completing the best year in the last six years.

5 Top Stocks That Popped in 2020 and Have Strong Upside Left

Delta Air Lines

Forterra

SYNNEX

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Invest in These 5 Stocks With Solid Relative Price Strength

Omnicell

Oasis Midstream Partners

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

News for Amedisys Stock (AMED)